{"protocolSection":{"identificationModule":{"nctId":"NCT06474455","orgStudyIdInfo":{"id":"SHR-9839-201"},"organization":{"fullName":"Shanghai Hengrui Pharmaceutical Co., Ltd.","class":"INDUSTRY"},"briefTitle":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","officialTitle":"A Phase IB/II, Open-Label, Multicentre Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-9839 for Injection in Combination With Other Therapies in Patients With Advanced Solid Tumors"},"statusModule":{"statusVerifiedDate":"2024-05","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-02","studyFirstSubmitQcDate":"2024-06-19","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-19","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors."},"conditionsModule":{"conditions":["Advanced Solid Tumors"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":156,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"SHR-9839 combined with SHR-A2009","type":"EXPERIMENTAL","interventionNames":["Drug: SHR-9839 ；SHR-A2009"]},{"label":"SHR-9839 combined with SHR-A1921","type":"EXPERIMENTAL","interventionNames":["Drug: SHR-9839 ； SHR-A1921"]},{"label":"SHR-9839 combined with pemetrexed + carboplatin","type":"EXPERIMENTAL","interventionNames":["Drug: SHR-9839 ； pemetrexed ；carboplatin"]},{"label":"SHR-9839 combined with Almonertinib","type":"EXPERIMENTAL","interventionNames":["Drug: SHR-9839 ； Almonertinib"]}],"interventions":[{"type":"DRUG","name":"SHR-9839 ；SHR-A2009","description":"SHR-9839 combined with SHR-A2009","armGroupLabels":["SHR-9839 combined with SHR-A2009"]},{"type":"DRUG","name":"SHR-9839 ； SHR-A1921","description":"SHR-9839 combined with SHR-A1921","armGroupLabels":["SHR-9839 combined with SHR-A1921"]},{"type":"DRUG","name":"SHR-9839 ； pemetrexed ；carboplatin","description":"SHR-9839 combined with pemetrexed + carboplatin","armGroupLabels":["SHR-9839 combined with pemetrexed + carboplatin"]},{"type":"DRUG","name":"SHR-9839 ； Almonertinib","description":"SHR-9839 combined with Almonertinib","armGroupLabels":["SHR-9839 combined with Almonertinib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of dose-limiting toxicity (DLT) (phase IB)","timeFrame":"21 days after the first dose was administered to each subject，Up to approximately 24 months."},{"measure":"Incidence and severity of adverse events (AE) and serious adverse events (SAE) and laboratory abnormalities (phase IB)","description":"Assess safety and tolerability of SHR-A2009 by way of adverse events (CTCAE v5.0)","timeFrame":"Begin from sign the ICF until the end of the safety follow-up period，Up to approximately 24 months."},{"measure":"Objective Response Rate (ORR) (phase II).","description":"Evaluated using RECIST 1.1","timeFrame":"The first treatment lasted until disease progression，Up to approximately 24 months."}],"secondaryOutcomes":[{"measure":"Incidence and severity of adverse events (AE) and serious adverse events (SAE) and laboratory abnormalities (phase II)","description":"Assess safety and tolerability of SHR-A2009 by way of adverse events (CTCAE v5.0)","timeFrame":"Begin from sign the ICF until the end of the safety follow-up period，Up to approximately 24 months."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged 18-75 years old (inclusive), regardless of gender.\n2. Patients with locally advanced or metastatic solid tumors confirmed by histology or cytology,.\n3. At least one measurable tumor lesion according to RECIST v1.1.\n4. ECOG performance score of 0-1.\n5. Life expectancy ≥ 12 weeks.\n6. Adequate bone marrow and organ function.\n7. Have the ability to informed consent, have signed the IRB / EC approved informed consent and dated, willing and able to comply with the treatment plan to visit the inspection and other procedural requirements.\n\nExclusion Criteria:\n\n1. Patients with active central nervous system ( CNS ) metastases.\n2. Spinal cord compression not be cured by surgery or radiotherapy.\n3. Subjects with uncontrollable tumor-related pain.\n4. Clinically uncontrollable the third space effusion.\n5. Anti-tumor treatments such as chemotherapy within 4 weeks prior to the first dose of study drug.\n6. Received \\> 30Gy chest radiotherapy within 24 weeks prior to the first dose of study drug.\n7. Major organ surgery or significant trauma within 4 weeks prior to the first dose of study drug.\n8. Concomitant other malignancies ≤ 3 years prior to the first dose of study drug.\n9. History of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis or inability to exclude interstitial pneumonitis; or other moderate-to-severe lung disease that severely affects lung function.\n10. Serious cardiovascular and cerebrovascular diseases.\n11. Patients with clinically significant bleeding symptoms within 3 months prior to the first dose of study drug.\n12. History of immunodeficiency, including HIV test positive.\n13. Active hepatitis B or hepatitis C infection.\n14. History of severe allergic reactions to any component of any study drug to be accepted.\n15. Known history of alcohol or drug dependence.\n16. Mental disorders or poor compliance ;\n17. Pregnant or lactating women.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Qingkai Zhou","role":"CONTACT","phone":"+8618205139261","email":"Qingkai.zhou@hengrui.com"}],"locations":[{"facility":"Zhejiang Cancer Hospital","city":"Zhejiang","state":"HangZhou","zip":"310005","country":"China","contacts":[{"name":"Zhengbo Song","role":"PRINCIPAL_INVESTIGATOR"}]},{"facility":"HeNan CANCER HOSPITAL","city":"Zhenzhou","state":"Henan","zip":"450003","country":"China","contacts":[{"name":"QiMing Wang","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.28034,"lon":119.16999}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009369","term":"Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000016190","term":"Carboplatin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000005493","term":"Folic Acid Antagonists"},{"id":"D000019384","term":"Nucleic Acid Synthesis Inhibitors"}],"browseLeaves":[{"id":"M18650","name":"Carboplatin","asFound":"System","relevance":"HIGH"},{"id":"M264","name":"Pemetrexed","asFound":"Strategies","relevance":"HIGH"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M8618","name":"Folic Acid","relevance":"LOW"},{"id":"M17546","name":"Vitamin B Complex","relevance":"LOW"},{"id":"M8619","name":"Folic Acid Antagonists","relevance":"LOW"},{"id":"T446","name":"Folic Acid","relevance":"LOW"},{"id":"T447","name":"Folinic Acid","relevance":"LOW"},{"id":"T448","name":"Folate","relevance":"LOW"},{"id":"T475","name":"Vitamin B9","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Hemat","name":"Hematinics"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":false}